Aurora Diagnostics Gets an Australian Owner
Aurora Diagnostics, founded and funded by Summit Partners since 2006, has been acquired by Sonic Healthcare (ASX: SHL), a global medical diagnostics company based in Macquarie Park, New South Wales, Australia, for $540 million. Aurora is a specialized laboratory company focused on anatomical pathology. It employs 1,200 staff, including approximately 220 pathologists, at 32 laboratories in 19 states. The labs process approximately 2.5 million accessions per year, received from about 23,000 referring physicians and through more than 100 hospital contracts across the country. According to Sonic, Aurora generated pro forma revenue of approximately $310 million (A$431 million) and pro forma... Read More »
Fresenius Makes Big Moves into China
Despite trade tensions between the United States and China, Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) announced three major deals to expand there. The global dialysis company acquired majority shares in several dialysis centers and renal hospitals and has plans to build even more. Because of its enormous population of more than 1.4 billion people, China is a long-standing target market for American marketers. As Fresenius’ press release announcing these deals on December 5 noted, approximately 10.8% adults in China have chronic kidney disease, or 120 million people. The company paid an undisclosed amount for a 70% stake in Guangzhou KangNiDaiSi Medical Investment Co., Ltd.... Read More »
Quest Diagnostics Bought and Sold Labs in October
The Labs, MRI & Dialysis sector saw a surge of deal making in October. The sector is a conglomeration of various healthcare segments, obviously, but clinical laboratories drove the nine announced transactions. Quest Diagnostics Inc. (NYSE: DGX) announced three of those deals, first with its divestiture of its India-based medical diagnostics business, consisting of 24 diagnostic labs across the sub-continent, including a large specialized diagnostics practice with three reference labs with expertise in oncology, genomics and precision medicine. The buyer was Strand Life Sciences, a portfolio company of Quadria Capital, a clinical research and diagnostics company that combines... Read More »
NeoGenomics Buys Oncology Lab Genoptix
It’s been two years since NeoGenomics, Inc. (NASDAQ: NEO) announced an acquisition, but now the time clock has been reset. On October 23rd, the cancer-focused genetic testing company made public its purchase of Genoptix, Inc., a privately held clinical oncology laboratory specializing in hematology and solid tumor testing. Genoptix has well-established relationships with community oncology practices, a sales force and pathologists that are experienced in serving oncologists, and customized reports that are considered to be the gold standard among community oncologists. Oncology practices are an important, and under-penetrated, channel for promoting NeoGenomics’ capabilities in... Read More »
RadNet Expands to Long Island Market
RadNet, Inc. (NASDAQ: RDNT), has acquired Medical Arts Radiology, which owns and operates 10 imaging centers in Long Island, New York. This is the second acquisition announced this year, following a string of joint ventures around the country. Medical Arts offers MRI, CT, PET/CT, X-ray, ultrasound, bone density and interventional procedures. The centers are located in Bay Shore, Commack, East Setauket, Huntington, Massapequa, Patchogue, Plainview, Smithtown, Bablyon and Stony Brook. In addition to servicing the existing patient base, the Medical Arts centers will be instrumental in providing diagnostic imaging to the approximately 200,000 patients of Emblem’s AdvantageCare Physicans, for... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
